No differences in the expression of APP and PS-1 as well as the APP cleavage products β-CTF and α-CTF were observed between anti-ERMAP mAb and control isotype Ab-treated AD groups (Fig. 4A, B). This evidence concerns the gene APP and Alzheimer disease.